Development of Metabolic Organ-Specific Biomarkers of Diabetes using a novel quantitative metabolomics approach: the liquid metabolic biopsy concept – MelODies

This approach, allowing to find these biomarkers in the circulating blood is called the liquid metabolic biopsy of targeted organs. My recent work based on semiquantitative metabolomics allowed to determine liver specific biomarkers. However, other organs key in T2D like skeletal muscle remain to be explored using a full quantitative approach.
The objectives of MelODies are 1) to extract T2D organ-specific metabolic signatures based on metabolites with altered arteriovenous differences (quantitative metabolomics) in a follow-up T2D protocol on multi-catheterized minipigs, 2) to model each organ metabolism and predict new biomarkers, and 3) to validate the organ-specific signatures in minipigs and then on two specialized human cohorts. MelODies will provide unique information on T2D onset and progression in individual organs with a single blood test.

no results to communicate yet

The data obtained will lead to better design of personalized and organ-targeted strategies to prevent the progression of early T2D to symptomatic disease by dietary or pharmacological treatments.

no results to communicate yet

Type 2 diabetes (T2D) is a multi-organ pathology affecting 58M people in Europe and 3.7 M people in France. It is also a silent disease. 22M people remain undiagnosed in Europe (700,000 in France), as its detection remains fortuitous, when the disease is already fully developed. The main clinical challenge of T2D is therefore before the occurrence of clinical symptoms. Thus, there is an urgent need for novel biomarkers of T2D onset and progression. Current biomarker discovery uses data-driven non-targeted metabolomics approach on venous blood or urine samples. Unfortunately, these metabolites provide a whole-body view, offering little mechanistic information on organ metabolism and function. Their potential for targets organ-specific therapeutics is then limited.
The originality of MelODies is to search biomarkers (metabolomics signatures) of organ-specific metabolic drifts occuring before the first clinical symptoms for better phenotyping early T2D onset and progression. This approach, allowing to find these biomarkers in the circulating blood is called the liquid metabolic biopsy of targeted organs. My recent work based on semiquantitative metabolomics allowed to determine liver specific biomarkers. However, other organs key in T2D like skeletal muscle remain to be explored using a full quantitative approach.
The objectives of MelODies are 1) to extract T2D organ-specific metabolic signatures based on metabolites with altered arteriovenous differences (quantitative metabolomics) in a follow-up T2D protocol on multi-catheterized minipigs, 2) to model each organ metabolism and predict new biomarkers, and 3) to validate the organ-specific signatures in minipigs and then on two specialized human cohorts. MelODies will provide unique information on T2D onset and progression in individual organs with a single blood test. The data obtained will lead to better design of personalized and organ-targeted strategies to prevent the progression of early T2D to symptomatic disease by dietary or pharmacological treatments.